|
Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors Clinical research trials and Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors. Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors  Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: Recruiting
Sponsor(s): Dana-Farber/Harvard Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and flavopiridol, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine with flavopiridol in treating patients who have solid tumors.
Details: OBJECTIVES: Primary - Determine the maximum tolerated dose of gemcitabine and flavopiridol in patients with solid tumors. Secondary - Determine the safety profile and toxic effects of this regimen in these patients. - Determine the pharmacokinetics of flavopiridol with and without gemcitabine in these patients. - Determine, using pharmacodynamic assays, the activity of flavopiridol as a cdk inhibitor in these patients. - Determine, using pharmacodynamic assays, the markers of this regimen in these patients. OUTLINE: This is a dose-escalation, multicenter study. All patients receive an initial dose of flavopiridol IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, patients receive gemcitabine IV over 60-150 minutes on days 1 and 8 and flavopiridol IV over 1-7 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose. Patients are followed at 30 days after study completion. PROJECTED ACCRUAL: A total of 40-80 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor for which gemcitabine is a treatment option OR for which no efficacious therapy exists - Must meet criteria for 1 of the following: - Measurable disease - At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan - Nonmeasurable disease, including any of the following: - Small lesions (less than 20 mm by conventional techniques OR less than 10 mm by spiral CT scan) - Bone lesions - Cytologically positive pleural or peritoneal disease - Elevated tumor markers (e.g., carcinoembryonic antigen, CA 125, CA 19-9, or other tumor marker) - Multinodular or confluent nonmeasurable pulmonary, hepatic, adrenal, intra-abdominal, or skin metastases - No active CNS metastases - Previously treated CNS metastases must be stable with no symptoms for 4 weeks after completion of treatment AND patient must be off steroid therapy or on a stable dose for at least the past 2 weeks - No known leptomeningeal metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - See Disease Characteristics - Bilirubin no greater than 1.5 mg/dL - SGOT no greater than 2.5 times upper limit of normal Renal - See Disease Characteristics - Creatinine no greater than 1.5 mg/dL OR - Creatinine clearance at least 50 mL/min Cardiovascular - None of the following within the past 6 months: - Myocardial infarction - Unstable angina - Transient ischemic attack - Cerebrovascular accident - No new cardiac arrhythmia possibly related to cardiac ischemia - No large and potentially symptomatic pericardial effusion - No cardiac disease that would preclude study participation Pulmonary - See Disease Characteristics - No pulmonary embolism within the past 6 months - No large and potentially symptomatic pleural effusion - No pulmonary disease that would preclude study participation Gastrointestinal - No intractable emesis - No grade 2 or greater chronic diarrheal disease within the past 6 months Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No active infection - No severe malnutrition PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No more than 2 prior chemotherapy regimens - Prior combined modality therapy (e.g., full-dose chemotherapy with radiosensitizing chemotherapy and radiotherapy) is considered 1 prior regimen if all therapy was delivered as part of 1 comprehensive treatment plan - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - No other concurrent chemotherapy Endocrine therapy - See Disease Characteristics Radiotherapy - See Chemotherapy - At least 6 months since prior radiotherapy to the lung parenchyma or mediastinum and no evidence of radiation pneumonitis on chest CT scan - At least 4 weeks since other prior radiotherapy and recovered - No prior radiotherapy to more than 50% of marrow volume - No concurrent radiotherapy Surgery - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GeoffreyShapiro, Study Chair, Dana-Farber/Harvard Cancer Center
Massachusetts General Hospital Cancer Center *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting David Ryan 617-724-0234
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Geoffrey Shapiro 617-632-4942
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Jeremy Kortmansky 212-639-3344
Additional Information:
Study ID Numbers: CDR0000339727; NCI-6051,DFCI-03110
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00072436
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
2. Combination Chemotherapy in Treating Patients With Advanced Cancer
3. S-3304 in Treating Patients With Advanced Solid Tumors
4. DHA-Paclitaxel With or Without Gemcitabine in Treating Patients With Advanced Solid Tumors or Unresectable Pancreatic Cancer
5. Chemotherapy in Treating Patients With Advanced Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
|
|
|
|
|
|
|
|
